Category: Money tips Release Date: 2006-04-03
Source: Anhui Emerging Author: Yuan
The Bank of China listed in the market after the channel established to run the pattern has continued, despite the Bank of China, Sinopec and other indicators of restricted shares to repeatedly adjust the pace of broader market up, but the strength of the short-term operation of the market has not changed the pattern of yin and yang of the Japanese K Line staggered pattern , showing that market's run to its own run for the characteristics of individual stocks relative prominence speculation has become a major market opportunity for profit.
From the market's overall operating point of view, a view that the news rules introduced a number of indicators on the stock to a certain extent, while the Bank of China after the listing of yin and continuously adjust the broader market also put pressure on short-term, and banking stocks dragged down the trend, Friday indicators of stock index closed Yinxian reflect the trend, but the market is relatively active in a number of individual stocks, but also shows indicators of stock market speculation is not subject to constraints, a number of institutions have the purpose of selecting a theme repeated speculation in stocks, and the formation of a large number of hot spots, right the short-term market sentiment have a certain concentration, and this is also on the broader market since the short-term stability and a better effect. Technically, the tape repeated short-term upside momentum with the characteristics of relatively insufficient, the market turnover has failed to effectively enlarge the indicator of the adjustment of stock market lacks upside momentum sustained, while the K-line on the form and Hu Zhi Shen Chengzhi Japanese K Line morphology shows the direction of short-term market trend with a choice, 10-day moving average is also facing challenges, showing the rise in short-term market access can continue to run needs to be further established. But deep KLCI trend perspective, the market closed out the high order small Yinxian, and showed a trend ascribed to obviously have a firmer shape, especially the index has another new high, which means there is still upside broader market opportunities, increase in wave is expected to continue to continue. Under the Shenzhen Composite Index currently has the right to judge the representativeness of market index, we can come to grasp the broader market from deep KLCI to run. As a result, we believe that the short-term stock will continue to own run-Quotes oscillation presentation, 3 (5) into the waves with the requirements under the extension is expected to broader market will continue to be upside next week.
Operation, short-term investors can consider choosing individual stocks to do short-term, and the present stock-picking can be established that a few basic ideas: First, the short-term technical adjustment of the full deliberation a breakthrough upside Quotes; second volume with the price of a good, strong features have formation; third outstanding performance of growth, since stock prices have a good supporting role. At this point, we have G modern (600.42 thousand) the potential of such an analysis on individual stocks.
G modern (600.42 thousand) for a Shanghai local drug class blue-chip stocks, the current share capital of 1.2375 billion shares in circulation, a quarterly earnings per share were 0.077 yuan, growth is extremely prominent. Its fundamental point of view, the Unit has the following highlights worthy of our attention:
1, performance continued to grow, to form the three main patterns. The company's products focus on three aspects, lipoic acid pharmaceutical raw materials, raw material medicine azithromycin, chemical and biological agents, in Lipoic Acid in bulk drugs, the company is currently the only master the analysis of sub-lipoic acid chiral technology, the manufacturers, their products 90% exported to Japan and Europe, is currently the largest manufacturing enterprises in azithromycin bulk drugs, the 2005 reached 100 tons, the market in Europe, India and South America, the domestic exports are close to 30% of the total export volume. As the international market, the demand for raw material medicine azithromycin continued growth and price recovery is expected in 2006, the company's export volume growth and performance will remain, in preparation products, there are a number of new varieties in 2006 will be the market, the company's In the controlled-release agents in the unique advantages of nifedipine controlled release tablets through the marketing, sales are expected to grow substantially. The company emerged in 2005 net profit of more than 50% of the growth performance of up to 0.45 yuan / share, a quarterly in 2006, its net profit remained rapid growth, with 2005 net profit increase of 26.37 percent year on year, indicating that the company still in a high-speed growing. The good performance of growth stocks for the current market, a popular hot spot, which makes the stock vulnerable to the attention of investors, which appears likely to stir up much higher than other classes individual stocks.
Second, growth of outstanding funds to attract large number of agencies involved. The company has maintained a close near the high-growth characteristics of the first quarter of this year net profit growth rate, up 26.37 percent year on year, showing excellent development momentum. CITIC Securities, according to Yao Jie research, expects 2006 and 2007 earnings per share to reach 0.64 yuan and 0.75 yuan, the stock target price should be 13 yuan. Huaxia Securities Zhu Yu, Zou new entrants that the company's earnings per share in 2006 will reach 0.66 yuan, the company will keep about 50% for three consecutive years of high growth characteristics of the stocks up targeting the 14 per hour. The China Merchants Securities Zhou Rui chemical drugs from domestic and Indian companies had the relative valuations of PE and DCF method with an absolute valuation results show that the stock has been undervalued in modern pharmaceuticals to give a "cautious recommendation" investment rating, target price 13.30 yuan. In the parent company's strong technical support, the company has gradually equipped with Xin Fu, pharmacy and medicine, and the sea are the main characteristics of Hengrui Medicine. In the growth stage of the lipoic acid is the biggest bright spot in 2005, 2005, the company's Alpha Lipoic Acid products both in the product mix or production level will be a big progress. Azithromycin in October 2005 U.S. patent expiration will allow the company doubled sales of the product. Sustained-release drug delivery companies have already formed a good product echelon, it will be the company's future sustainable and stable growth. It is precisely because of the high-growth characteristics of the unit has now attracted Yi Fonda, and many other funds involved in a large number of holdings, reflecting the sector's growth on the stock is extremely bullish.
Third, back strength of institutions, with a strong scientific and technological R & D capabilities. The company backed by Shanghai Institute of Pharmaceutical Industry, has a good high-tech background, strong research and development and innovation capacity, in 2005 obtained 13 production orders, authorizations to conduct clinical testing and production approval to declare product 24, in the research products 6 months. The company's controlling shareholder of Shanghai Institute of Pharmaceutical Industry, the hospital affiliated enterprises for the SASAC, in accordance with the requirements of the SASAC, the future will be to seek the overall market, while the hospital system, China's pharmaceutical industry is the largest and strongest comprehensive research and development institutions, a lot of products with better market prospects, if the realization of high-quality asset injection will allow the company has a leap growth.
Technically, the stock ex-rights as long as more than a month after the formation of a sideways platform for continued convergence of stock prices after the first adjustment after the unit has received two-yang, the formation of heavy volume upside momentum, with the completion of large triangular order to launch a new Shenglang breakthrough Quotes of the technical requirements.
Therefore, we believe, G modern (600.42 thousand) as a blue-chip high-growth blue-chip stocks, the rise in the short-term has entered a new phase of accelerated Quotes, short-term investors can focus on objects.
